Thursday , July 18 2019
Home / argentina / A group of scientists believe they have the key to definitive cancer treatment

A group of scientists believe they have the key to definitive cancer treatment




Cancer is one of the biggest causes of death in the world. According to World Health Organization (WHO) data, it currently affects 1 out of 5 men and 1 out of 6 women and 9.6 million people died globally in 2018 after the disease.

There are several treatments that try to eradicate cancer, however, until now there is no one who definitely ends up with this condition.

It has recently been reported that a group of Israeli scientists from a pharmaceutical lab Accelerated evolutionary biotechnology (AEBi) could change the prospects we have about cancer, as they have announced, very close to determining much more effective treatments than existing ones to detect this disease.

"We believe we will offer a full cancer drug in one year," he said. Dan Aridor, president of AEBi.

"It will be effective from the first day, it will take several weeks and will have minimal or no side effects at much lower costs than most other treatments on the market," he added.

According to The Jerusalem Post, this treatment, known as "MuTaTo" (a toxin with more meta), is an antibiotic product of toxin combinations that specifically attack cancer cells and eliminate the possibility of reappearance of the disease. .

For its part Ilan Morada research leader told the Israeli channel that experts would be responsible for analyzing the cancer type of each patient in order to provide an antibiotic specially designed to treat their disease.

That is, although it is intended to create a generic drug, cancer treatment by "MuTaTo" will be specifically designed for each person, analyzing samples of each biopsy.

Morad has compared the concept of "MuTaTo" with a triple drug that has helped change AIDS from automatic death penalty to chronic illness.

But unlike HIV and AIDS, where patients need to take drugs permanently, with "MuTaTo", the cells would be killed, so the treatment could stop in just a few weeks.

As expected, this revelation has generated all sorts of reactions, and there are those who take these statements with skepticism, pointing out that the study is limited and that there is no scientific publication that would support it.

One of them is Len Lichtenfeld, director of the American Cancer Society, who says it is too early to conclude that the drug will work successfully on people because it has only been experienced by mice up to now.

"Unfortunately, we must be aware that this is far from being an effective treatment for people with cancer and even less cure," he wrote in his personal blog.


Source link